Stanford scientists say they found a natural molecule that cut appetite in half in lab animals without causing the nausea that plagues Ozempic users.
Quick Take
- Stanford Medicine researchers used artificial intelligence to identify a 12-amino-acid peptide called BRP that suppresses appetite in mice and pigs.
- A single injection cut food intake by up to 50% in the hour after dosing, with no signs of nausea or food aversion.
- Obese mice given daily BRP shots for two weeks lost fat while untreated mice gained weight.
- The molecule has not been tested in humans, so its safety and effectiveness in people remain unknown.
What Stanford Researchers Found
Stanford Medicine researchers identified BRP, a naturally occurring peptide, through a computer-driven screening process designed to find molecules that regulate hunger. Tests on mice and minipigs showed the compound suppressed appetite and reduced weight gain without triggering the nausea or food aversion often linked to drugs like Ozempic. Researchers chose minipigs because their metabolism and eating habits more closely resemble human biology than mouse models do.
The effect was strong and fast. A single injection of BRP given before feeding time cut food intake by as much as 50% during the following hour, in both mice and minipigs. Over a longer stretch, obese mice that received daily BRP shots for 14 days lost about 3 grams on average, while untreated mice gained roughly the same amount. Nearly all the weight loss came from fat, not muscle or water.
How the Discovery Compares to Ozempic
Ozempic and similar GLP-1 drugs have reshaped weight-loss treatment but carry well-known downsides, including nausea, vomiting, and high discontinuation rates. Roughly half of patients stop taking GLP-1 medications within their first year, according to industry actuarial research. BRP’s appeal rests on early animal data suggesting it might achieve similar appetite suppression without those side effects, though no study has directly compared the two compounds in a controlled trial.
This is not Stanford’s first appetite-molecule discovery. In 2022, Stanford researchers identified Lac-Phe, a different molecule made from lactate and phenylalanine that forms naturally after intense exercise. Lac-Phe reduced food intake in obese mice by about 30%. BRP and Lac-Phe are separate findings from separate research efforts, even though both get compared to Ozempic in public discussion.
Why Animal Results Don’t Guarantee Human Success
No human clinical trial of BRP has been reported. The strongest results so far come from short experiments: a one-hour feeding test and a two-week dosing period in mice. Neither measures long-term weight maintenance, tolerance, rebound appetite, or chronic toxicity. Researchers would need registered human trials with placebo comparisons, adverse-event tracking, and dosing studies before BRP could be considered a real alternative to approved weight-loss drugs.
History suggests caution is warranted. A review of biomedical research found that more than 92% of drug candidates that work in animals fail to translate into successful human treatments, usually due to unexpected toxicity or a lack of real-world effectiveness. That statistic doesn’t predict what will happen with BRP, but it explains why scientists treat early animal findings as promising leads rather than finished cures.
The Bigger Picture on Natural Health Claims
Calling BRP a “natural Ozempic” carries a built-in assumption that natural compounds are automatically safer than manufactured drugs. Health experts caution that “natural” does not mean risk-free; many natural substances still require rigorous safety testing before they can be trusted for regular use. BRP’s lack of observed side effects so far comes from short animal studies, not from any comparison against semaglutide in people.
The timing matters too. GLP-1 drugs already cost the U.S. health system tens of billions of dollars a year, and demand keeps climbing. That financial pressure creates a strong incentive to find cheaper or more tolerable alternatives, which may explain why early animal findings like BRP draw outsized attention before any human data exists. For now, BRP remains a laboratory discovery worth watching, not a product available to anyone.
Sources:
youtube.com, med.stanford.edu, humanperformancealliance.org
